Loading organizations...
§ Private Profile · San Francisco, CA, USA
Technology company that developed a mobile app for event discovery and social networking for consumers, focused on real-world social interactions.
IRL has raised $208.0M across 5 funding rounds.
Key people at IRL.
IRL has raised $208.0M in total across 5 funding rounds.
IRL was a technology company that developed a mobile application for discovering and joining local events, group chats, and community activities, aiming to facilitate real-world social interactions, encouraging users to "do more together." Operating as a consumer app within the social networking and event discovery sectors, the platform targeted general consumers seeking local communities and activities. Despite its mission to connect people, specific details regarding its operational scale, business model, or headquarters were never publicly disclosed during its active period. Information concerning lead investors, key partners, notable customers, founding year, or the names of its founders also remained publicly unavailable. IRL has since ceased operations, permanently shutting down as of June 27, prior to 2026, with no additional developments reported.
IRL Technology is a software company specializing in tailored solutions for the pharmaceutical industry, focusing on optimizing reporting processes for drug manufacturers and managing limited-distribution and patient access programs.[1] It serves pharmaceutical companies by streamlining operations, enhancing productivity, and improving patient care through innovative healthcare technology.[1] Incorporated recently as IRL TECH LTD, the company develops ready-made interactive leisure and entertainment software, though its primary emphasis is on pharma-specific tools, indicating early-stage growth momentum in a niche but critical sector.[2]
IRL TECH LTD was incorporated on 14 February 2025 as a private limited company in London, England, with its registered office at 54 Lambs Conduit Street, WC1N 3LW.[2] Specific founders or key partners are not detailed in available records, but the company's rapid setup aligns with the growing demand for specialized pharma software.[1][2] Early traction appears tied to its mission in healthcare tech, with first accounts due in November 2026, signaling a startup in its initial operational phase.[2]
IRL Technology rides the trend of digital transformation in healthcare, particularly pharma's push for efficient compliance and patient-centric programs amid rising drug complexity and regulations.[1] Timing is ideal post-2025 incorporation, as AI and automation accelerate in limited-distribution drugs (e.g., specialty therapies), with market forces like supply chain pressures favoring streamlined reporting tools.[1][2] It influences the ecosystem by empowering manufacturers to focus on innovation over bureaucracy, potentially scaling to support broader patient access in a $1.5 trillion global pharma market.
Next steps for IRL Technology likely include launching its first products and securing initial pharma clients, with accounts and confirmation statements due in 2026 providing early growth signals.[2] Trends like AI integration in drug management and stricter FDA reporting will shape its path, amplifying demand for its optimizations.[1] Its influence could evolve from niche provider to key enabler in pharma tech, especially if it expands beyond reporting into full patient journey platforms—tying back to its core promise of revolutionizing healthcare through targeted software.[1]
Key people at IRL.
IRL has raised $208.0M in total across 5 funding rounds.
IRL's investors include Serena Dayal, AirAngels, Altair Capital Management, Banana Capital, Eclipse Ventures, Floodgate, Freestyle Capital, Goodwater Capital, Greylock, Hanaco Ventures, Long Journey Ventures, Makers Fund.
IRL has raised $208.0M across 5 funding rounds. Most recently, it raised $170.0M Series C in June 2021.
